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in themarket. Given the discrepancies between the decisions of the regulators and
the payers, drug manufacturers are obliged to demonstrate a product’s value to
patients and payers, as well as to show that it is safe and efficacious to regulators.
The incorporation of the payers’ viewpoint in the development process will ease
the gap between stakeholders.
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OBJECTIVES: Incentive-based schemes, in which patients are rewarded formaking
behaviour changes or reaching treatment goals, are becoming more common in
healthcare worldwide. Issues surrounding the cost effectiveness of behaviour
change, as well as the ethical implications of rewarding members of society who
exhibit inappropriate behaviours, are some of the issues which must be taken into
account when considering these schemes in real-life. The aim of this study was to
provide an account of incentive-based schemes currently under investigation, in
an effort to determine where the perceived benefits of these schemes may lie for
future implementation. METHODS: A Clinicaltrials.gov search was performed to
identify trials that specifically tested the use of incentives in encouraging behav-
iour modification in target populations. RESULTS: A total of 76 clinical trials, pre-
dominantly based in North America, were identified as appropriate for analysis.
The most commonly targeted groups included drug dependant individuals, over-
weight individuals (with exercise orweight-loss programmes) and smokers, imply-
ing that these schemes are most commonly used to induce lifestyle changes that
promote health. Most trials looked at the clinical-effectiveness of incentives at
achieving behaviour change, with minimal emphasis on the cost-effectiveness of
adding the incentive. The majority of the trials (43/76, 57%) used monetary or
voucher reimbursement systems as the incentive for patient behaviour modifica-
tion, with 10 additional schemes providing the opportunity to win a prize. Only 1
scheme directly linked reimbursement to treatment costs by providing a cycle of
treatment for free if the patient sustained compliance for a specified period.
CONCLUSIONS: The scope for the use of incentive-based schemes is broad, with
potential applications in numerous different diseases in which good compliance is
required; not just those which require lifestyle change. However, further economic
analysis of the cost-effectiveness of such schemes is essential before they are
implemented more widely.
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OBJECTIVES: With the advancement of the China health care reform and the in-
creasing health care expenditure, it is imperative to explore other billing methods
in addition to the existing item-based billing. Since 1980s, US and many other
countries have adopted DRGs to manage heath care insurance to control health
care expenditure and achieved positive outcomes. The objectives of this study are
to understand experiences from other countries in the implementation of DRGs
and make recommendations on how to adopt DRGs in China. METHODS: This
study started in 2003. It is composed of three phases: phase one is to study how
DRGs are implemented in the US, Australia, and Germany; phase two, the core part
of this study, is to analyze the grouping method. Based on learnings from US,
Australia, and Germany, we randomly collected 700000 patient records taking
place between 2002 and 2005 from 12 tier-one Beijing hospitals, developed a theo-
retical DRGs grouping model, and completed over 600 DRGs automated grouping
programs tailored for China; phase three contains analyses on the basic require-
ment of relevant policy and technology support to implement DRGs. RESULTS:
DRGs has been demonstrated to be an effective approach to manage health care
insurance in many countries. Considering China’s special situations (population,
health insurance system and policy environment), we developed and piloted DRGs
in 12 tier-one hospitals in Beijing in 2010. We will further evaluate the impact of
this program in the future. CONCLUSIONS: The successful implementation of
DRGs depends on an appropriate policy environment and mature technology sup-
port. Currently China is not ready to launch DRGs nationally yet due to the lack of
policy environment and technology support.
Health Care Use & Policy Studies – Drug/Device/Diagnostic Use & Policy
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OBJECTIVES: Public health policy is understood to be a major determinant of over-
all population health. However, developing public health guidance can be difficult
due to the lack of sufficient evidence on the effectiveness and cost-effectiveness of
possible interventions. The objective of this studywas to identify themajor gaps in
the evidence base that has been used to develop public health guidance.
METHODS: The gaps identified by the UK National Institute for Health and Clinical
Excellence (NICE) in the evidence that was used for the development of their 31
public health guidance documents published as of December 2010 were assessed
and compared. RESULTS: The most prevalent data gap, identified by 25 of the 31
guidance documents, was a lack of evidence on the effectiveness of public health
interventions in specific subgroups of the population, particularly ethnic minori-
ties, age subgroups and those from disadvantaged backgrounds. The secondmajor
gap in the evidence, discussed by 21 documents, was a lack of data specific to the
country of interest (in this case, the UK). Nineteen documents reported the lack of
cost-effectiveness evidence as a barrier to developing public health guidance and 4
of these specifically noted the difficulty of generating QALYs in the public health
arena. Further major data gaps included a lack of well-designed studies (14 docu-
ments), a lack of long-term outcomes (13), insufficient evaluation of which ele-
ments of an interventionmake it effective (9) and a lack of evidence on the relative
effectiveness of interventions (8). CONCLUSIONS: Research into public health in-
terventions and issues is of paramount importance. Researchers should focus ef-
forts upon identifying particular subgroups in which interventions are particularly
effective or ineffective and on generating country-specific data. Cost-effectiveness
data is particularly lacking; one solution would be to devise newmethods of QALY
measurement in public health situations.
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OBJECTIVES: This study investigates the extent to which geographic variation in
adequacy of primary care and specialist supply explains variation in patient use of
prescribed medications to treat chronic conditions. METHODS: Generalized Least
Squares regression with period random effects was used on a pooled data set of
monthly (May 2006 to Oct 2010) IMS Health data for 360 Metropolitan Statistical
Areas (MSAs). The dependent variablewas totalmonthly prescriptions perMSA for:
(1) Statins, (2) PPIs, (3) Anti-psych, and (4) asthma/COPD. Separate regressionswere
estimated by therapeutic category and by payer type. Explanatory variables include
monthly: (1) size of the population with the chronic condition;(2) economic envi-
ronment; (3) dummy event variables; and (4) level of Rx advertising. Estimates of
the shortfall of primary care providers and specialists in each State in 2010 are
included as explanatory variables. For state-level shortfall, provider demand esti-
mates were based on national healthcare use and delivery patterns applied to each
State’s population controlling for demographics, rates of uninsured, and obesity
rates. RESULTS: There exists a direct correlation between estimated adequacy of
primary care and specialist (cardiologist, gastroenterologist, psychiatrist, pul-
monologist, and allergist) supply and volume of prescriptions. The patterns are
relatively consistent across therapeutic areas. For the Statinmarket, each 1% short-
fall of cardiologists is associated with 0.36%, 0.43%, and 0.79% decrease in Statin Rx
volume for the commercially insured,Medicare, andMedicaid populations, respec-
tively. Each 1% shortfall of primary care providers is associated with decreases in
volume across in the commercially insured (0.15%) and Medicaid (0.83%)
populations. CONCLUSIONS: This research suggests that controlling for economic
and population risk factors, greater inadequacy of physician supply is associated
with lower use of prescriptions for treating chronic conditions. Physician shortages
disproportionally affect access to medications for the Medicaid population, fol-
lowed by the Medicare and commercially insured populations.
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OBJECTIVES: The Welsh Assembly Government introduced free prescriptions for
all on 1st April 2007. In the other UK countries, prescriptions were around £6 each,
although children, elderly and other exemptions applied. This study evaluated
whether the Welsh policy change impacted levels of prescribing.METHODS: Total
numbers of prescription itemswere calculated for eight 12-month periods between
1st July 2001 and 30th June 2009 from The Health Improvement Network (THIN),
which contains anonymised longitudinal UK primary care data. The number of
prescriptions was divided by number of actively registered patients for each time
period, country and age category (0-21, 22-59 and 60 years old). Percentage
changes between periods were calculated and all results described. RESULTS: In
Wales therewere 19.5 prescriptions/patient in the 2001/2002 period, which steadily
increased to 26.9 in the 2008/2009 period. In England, prescriptions/patient in-
creased from 15.1 to 21.3, Scotland 15.4 to 20.2, Northern Ireland (NI) 16.7 to 21.9.
The percentage change between 2006/2007 and 2007/2008 was 4.2% in Wales, 4.9%
England, 3.1% Scotland, 4.3% NI. The change within the 0-21 year olds was 4.0%,
1.7%, 2.6% and 0.8% respectively. For 22-59 year olds it was 6.6%, 3.0%, 2.5% and
3.7% respectively. For 60 year olds it was 2.8%, 5.1%, 2.9% and 4.3% respectively.
CONCLUSIONS: The descriptive results suggest that overall the policy change did
not seem to impact levels of prescribing in Wales as the percentage change was
similar across countries. However, the percentage change for the 0-21 and 22-59
age groups was higher in Wales, whereas the percentage change for the 60 age
group, who were already exempt from prescription charges, was lower. This could
suggest that prescribing increased for patients who were previously most affected
by prescription charges. Future studies could evaluatewhether prescribing of certain
drug classes, especially those including over-the-counter products, was affected.
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